We designed a study to discover BPDCN-associated mutations based on sequencing the complete exome of three tumors, matched with normal samples. The discovered mutations detected were then further ...
The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet ...
A blastic plasmacytoid dendritic-cell neoplasm is a rare tumor with very aggressive clinical behavior and no established treatment. 1 Available treatment options include aggressive multiagent ...
BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines help ...
CD123 is universally and highly expressed on BPDCN cells. Because CD123 expression is significantly lower on normal hematopoietic stem cells, it provides a distinct "therapeutic window," allowing for ...
MPN-BP transformation is driven by sequential mutations disrupting genomic stability, with TP53 mutations being strong predictors of progression. TP53 mutations confer a selective growth advantage, ...
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Clinical trials frequently include multiple end ...
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer This phase I/II, open-label, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results